Nanobodies Neutralizing Lassa Virus

Lassa Hemorrhagic Fever (LHF) is a serious disease caused by infection with Lassa virus (LASV) – highly prevalent in West Africa and spreading globally. LASV is associated with high morbidity and mortality rates, annually infecting 100,000 to 300,000 individuals and causing 5,000 deaths. Developing prophylactics and treatment for LASV is difficult due to challenges in inducing neutralizing antibodies and producing their target, the LASV glycoprotein trimer (GPC).

A Key Advancement for Human Norovirus Research and Reverse Genetics

The HEK293T/T7 cell line is a novel development in virology research, particularly for studying human noroviruses. This cell line expresses the T7 RNA polymerase, a key enzyme used in reverse genetics systems. Unlike existing technologies, the HEK293T/T7 cell line offers the unique advantage of being able to produce functional T7 RNA polymerase, which is essential for driving transcription from T7 promoters.

Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice

This technology includes the development of transgenic mice with a targeted gene mutation that flanks exon 8 of the Ikzf2 (Helios) gene using loxP sites. These Ikzf2 fl/fl (floxed) mice allow researchers to selectively delete the Ikzf2 gene in specific tissues or cells by crossing them with mice that express Cre recombinase under tissue-specific promoters.

Immunotherapy for Treating HER2-Positive Breast Cancer

This technology includes a novel immunotherapy approach designed to target HER2-positive breast cancer cells. It leverages a specific mechanism to enhance the immune system's ability to identify and destroy these cancer cells. The technology demonstrated significant potential in pre-clinical in vivo studies, suggesting it could improve treatment outcomes for patients with HER2-positive breast cancer

Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development

The Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified as the most efficient for transfection and infection by HEV.

Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs

The pork tapeworm, Taenia solium, is endemic in most of Asia, Latin America, and Sub-Saharan Africa. The risk of infection is increased in regions where pigs are raised in closed proximity to humans, with migration from endemic regions being directly proportional to the prevalence of infection in high-income countries. Human infection by T. solium occurs following oral ingestion of eggs passed in human feces from an infected carrier. The larvae can travel anywhere in the human body.

Chikungunya Vaccine License Receives LES Deal of Distinction Award

The NIH Technology Transfer Program was honored with its record 7th “Deal of Distinction Award” at the 2025 Licensing Executives Society Annual Meeting.  This award was given to NIH and its licensee Bavarian Nordic for the deal that led to the new chikungunya virus vaccine Vimkunya®. Vimkunya received FDA approval on February 14, 2025, as the first virus-like particle (VLP) single-dose chikungunya vaccine and the first chikungunya vaccine for individuals over the age of 12. .

NIAID License to BioNTech Facilitated the Development of an mRNA Vaccine for SARS-CoV-2 (Comirnaty®)

The LES Deal of Distinction award recognizes major business transactions involving licensing, that exemplify best practices and creativity to achieve strategic product development objectives, with a significant impact on advancing innovation in the industry sectors that comprise LES which includes pharmaceutical and biomedical technology. This LES award specifically recognizes two deals that were negotiated by NIAID technology transfer officers with an array of partners in industry and academic institutions, or Industry University Government Interface (IUGI) sector.